恒瑞医药(600276.SH):SHR-3792注射液获批开展晚期实体瘤的临床试验

智通财经
13 Apr

智通财经APP讯,恒瑞医药(600276.SH)发布公告,近日,公司子公司上海恒瑞医药有限公司、苏州盛迪亚生物医药有限公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于SHR-3792注射液的《药物临床试验批准通知书》,将于近期开展临床试验,同意本品开展晚期实体瘤的临床试验。

SHR-3792注射液是公司自主研发的创新型抗肿瘤候选药物,在临床前动物模型中展现了良好的抗肿瘤活性。经查询,目前国内外尚无同类药物获批上市。截至目前,SHR-3792注射液相关项目累计研发投入约3,271万元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10